Is Semaglutide Legal in Australia? (2026 Research Status)
Here is a number that reshaped the conversation around metabolic health. In the STEP 1 trial, adults with overweight or obesity taking once-weekly semaglutide 2.4 mg lost about −14.9% of their body weight over 68 weeks. Placebo users lost −2.4% Wilding et al., 2021.
That single result sent demand for semaglutide soaring worldwide. It also brought a wave of confusion about where the compound is legal and how to access it.
If you are in Australia, you have likely seen contradictory information. Pharmacies post shortage notices. News outlets report on regulatory crackdowns. Online forums fill with speculation. What is actually true?
This guide breaks down the current legal status of semaglutide in Australia as of 2026. It covers what is approved, what is restricted, and what the research looks like — so you can decide based on evidence, not hype.
What Is Semaglutide?
Semaglutide is a synthetic version of the human glucagon-like peptide-1 (GLP-1) hormone. GLP-1 is an incretin — a gut-derived signalling molecule released after eating. It helps regulate blood glucose and appetite.
Semaglutide is built to resist fast breakdown by the enzyme DPP-4. This gives it a half-life of roughly one week, which allows once-weekly dosing.
For a deeper dive into the pharmacology and research history of this compound, see our full semaglutide compound profile.
Is Semaglutide Legal in Australia?
Yes — but with significant conditions. Semaglutide is not a banned substance in Australia. It is classified as a Schedule 4 (S4) Prescription Only Medicine under the Poisons Standard (also known as the SUSMP). This means:
- You cannot buy it over the counter.
- You cannot legally obtain it without a valid prescription from an Australian-registered medical practitioner.
- It falls under the same rules as other prescription-only medications.
The Therapeutic Goods Administration (TGA) is Australia’s medicines regulator. It has approved specific semaglutide products for defined uses. Those approvals mean the product was checked for quality, safety, and efficacy in a particular clinical setting.
TGA-Approved Semaglutide Products
As of 2026, two branded semaglutide products hold TGA registration:
Ozempic (semaglutide, lower doses)
Ozempic contains semaglutide at 0.25 mg, 0.5 mg, and 1 mg per injection. It is approved for adults with type 2 diabetes to improve blood sugar control.
In the STEP 2 trial, semaglutide 2.4 mg once weekly lowered HbA1c and body weight in adults with type 2 diabetes and overweight or obesity Davies et al., 2021. However, the lower Ozempic doses approved in Australia are marked for blood sugar management, not weight loss.
Wegovy (semaglutide, higher doses)
Wegovy contains semaglutide at doses up to 2.4 mg per injection. It is approved for chronic weight management in adults with a BMI of 30 kg/m² or above. It can also be used at 27 kg/m² with at least one weight-related health condition. It is meant to be used alongside a reduced-calorie diet and increased physical activity.
This is the product most tied to the weight-management results that have driven public interest.
The distinction matters. A doctor prescribing Ozempic off-label for weight loss is using it outside the TGA-approved indication. Prescribing Wegovy for the same purpose is within the approved label. This nuance often gets lost in public discussion.
The Compounding Question
One of the most confusing parts of the Australian semaglutide landscape involves compounded versions. Compounding pharmacies prepare customised medications for individual patients under prescription. For a time, some Australian pharmacies made compounded semaglutide, often at lower prices than the branded products.
However, the TGA has taken an increasingly firm stance on this practice. Key points:
- Semaglutide is not currently approved as an active ingredient for compounding the way some other peptides or hormones may be. The TGA has warned about compounded semaglutide, citing concerns about quality, sterility, and dose accuracy.
- Products from compounding pharmacies do not get the same quality checks as TGA-registered medicines.
- Rules around compounded peptides in Australia have tightened a lot. For a broader look at the changing legal status of peptide compounds, see our guide: Are Peptides Legal Again? The 2026 Guide.
If you see compounded semaglutide at a price that seems too good to be true, pay attention. Research shows the quality of a drug matters. Substandard dosing or contamination can bring risks that do not show up in trial data, where the compound is made under strict quality controls.
Importation Rules
Australia’s Personal Importation Scheme (PIS) lets people bring certain prescription medications into the country for personal use under specific conditions. Several key limits apply:
- The medication must be for a legitimate medical condition you are being treated for.
- It must not be a prohibited import under Australian customs law.
- A valid Australian prescription is usually required.
- Quantities are generally capped at a maximum of three months’ supply per importation.
- The product must be declared to customs.
Importing semaglutide from overseas without a valid Australian prescription may break both the Therapeutic Goods Act 1989 and the Customs Act 1901. Importing compounded products from unregulated suppliers carries the same risk. Penalties can be significant.
The Supply Shortage Problem
Australia has had on-and-off semaglutide shortages since 2022, driven by a surge in global demand. These shortages have created knock-on effects:
- Some patients with type 2 diabetes who rely on Ozempic have struggled to get their medicine.
- Some people have turned to unregulated online sources — a practice with serious risks. Products from these channels may be fake, contaminated, wrongly dosed, or stored badly.
- Shortages have also pushed demand for compounded alternatives, which, as noted above, sit in a regulatory grey zone.
If you want legitimate ways to access semaglutide in Australia, we have a detailed resource: Where to Buy Semaglutide in 2026.
What Does the Research Tell Us?
It is worth stepping back from the rules to look at what the clinical evidence shows — and its limits.
The STEP (Semaglutide Treatment Effect in People with Obesity) trial programme is the largest body of evidence on semaglutide’s effects on body weight. Across several trials, the data suggest that semaglutide 2.4 mg may support meaningful weight loss when used with dietary and lifestyle changes.
The STEP 5 trial extended these findings. It suggested that weight-management effects may hold over a two-year treatment period Garvey et al., 2022.
Several important caveats apply:
- Individual responses vary. Not all trial participants saw the same amount of weight change. The figures reported are group averages.
- Side effects are common. Gut problems — nausea, vomiting, diarrhoea, and constipation — were frequent in trial groups, especially during dose increases.
- Long-term data beyond two years remain limited. Most published trials ran for 68 to 104 weeks.
- Weight regain after stopping is a documented concern. Research suggests that stopping semaglutide may lead to partial or full regain of lost weight over time.
None of this says what semaglutide will or won’t do for any one person. It is context — the kind that helps you read headlines and talk with your healthcare provider.
Where Things Stand in 2026
To summarise the current Australian landscape:
| Status | Detail |
|---|---|
| Legal status | Schedule 4 — Prescription Only |
| TGA-approved products | Ozempic (type 2 diabetes), Wegovy (weight management) |
| Compounded semaglutide | TGA has raised significant quality and regulatory concerns |
| Importation | Permitted under Personal Importation Scheme with valid prescription and quantity limits |
| Supply | Intermittent shortages continue |
| Research base | Robust short-to-medium-term data; long-term data still emerging |
The legal framework in Australia is clear in principle. Semaglutide is a prescription medicine — not a supplement, not an over-the-counter product, and not a grey-market research chemical. The hard part is navigating access, and separating real science from noise.
Frequently Asked Questions
Can I buy semaglutide in Australia without a prescription?
No. Semaglutide is a Schedule 4 (Prescription Only) medicine in Australia. You need a valid prescription from an Australian-registered medical practitioner to get it legally from a pharmacy.
Is compounded semaglutide legal in Australia?
The legal status of compounded semaglutide is a nuanced and changing area. The TGA has raised concerns about compounded semaglutide products, and its guidance has tightened. If you are considering this route, it is worth understanding the risks and the current position — our article on peptide legality in 2026 covers this in more detail.
What’s the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are approved for different uses and at different dose ranges. Ozempic (lower doses) is TGA-approved for type 2 diabetes. Wegovy (up to 2.4 mg) is approved for chronic weight management in eligible adults. They are distinct products with separate registrations.
Can I import semaglutide from overseas?
Australia’s Personal Importation Scheme may let you bring prescription medicines in for personal use, under specific conditions. You need a valid Australian prescription and must meet quantity limits. Importing without proper paperwork, or from unregulated sources, may break Australian law.
Does research support semaglutide for long-term use?
Clinical trials such as STEP 5 suggest that semaglutide may support sustained weight management over a two-year treatment period Garvey et al., 2022. Long-term data beyond this window are still emerging, and individual outcomes can vary. This is a question to discuss with a qualified healthcare provider who knows your specific circumstances.
